RxDoctor Payments Data

Adam Klang, MD

Internal Medicine · Bakersfield, CANPI 1386732246

Payments from drug & device makers

$1,496in general payments, 2019–2025

Across 63 payments — averaging $23.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$436
  • Johnson & Johnson$317
  • Novo Nordisk$140
  • Teva Pharmaceuticals USA, Inc.$120
  • Astellas Pharma US Inc$116
  • Dexcom, Inc.$65
  • plus $301 from 11 others

What the payments were for

  • Food & beverage$1,38292%
  • Education$1148%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,496 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,030,843
Medicare patients
705
Services billed
10,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban353$88,318
JanuviaSitagliptin Phosphate155$24,905
XareltoRivaroxaban67$19,041
JardianceEmpagliflozin20$8,026
Atorvastatin Calcium1,012$6,633
Midodrine Hcl181$6,395
Gabapentin508$5,090
Enoxaparin Sodium56$4,365
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$4,124
FarxigaDapagliflozin Propanediol11$3,803
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc34$3,763
Memantine Hcl161$3,401
Divalproex Sodium150$3,312
Pantoprazole Sodium567$3,197
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate98$3,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$436$88,318353 claims
Johnson & JohnsonXarelto$317$19,04167 claims
Boehringer IngelheimJardiance$15$8,02620 claims
AstraZenecaFarxiga$33$3,80311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →